In melanoma, radiosurgery may combine well with immunotherapy, especially PD-1 inhibitors

June 25, 2018, CU Anschutz Medical Campus

Doctors often treat melanoma with drugs that unblind the immune system to cancer. And brain metastases associated with melanoma are often treated with precisely targeted radiation known as radiosurgery. Now a University of Colorado Cancer Center study published in the Journal of Neuro-Oncology shows a potential advantage of combining these two techniques: Of 38 melanoma patients treated with immunotherapy and radiosurgery between 2012 and 2017, median overall survival was not reached, meaning that so many of these patients (who historically have had very poor prognosis) were still alive when data was analyzed that it was impossible to predict how long a patient treated in this way would be expected to live. Importantly, the study also shows a significant difference in cancer control depending on the type of immunotherapy used. In melanoma, brain metastases are a major cause of mortality. Patients treated with anti-CTLA4 immunotherapies saw the development of new brain metastases at median 3.1 months, whereas the median was not reached for patients treated with anti-PD-1 immunotherapies.

"We decided to look at this because it's something we commonly do in the clinic. We use immune checkpoint inhibitors, and at the appearance of metastases, we're using radiosurgery. Big studies have shown a dramatic increase in survival for patients with , and our study hints at one possible reason why: There may be an underlying synergy between these therapies," says Tyler Robin, MD, Ph.D., senior resident in at the CU School of Medicine and the paper's first author.

The exact mechanism of this synergy is still under investigation, but studies have shown that radiation treatments can increase the PD-L1 signal on tumors essentially giving the anti-PD-1 or anti-PD-L1 inhibitors a target to act on.

Of the 38 patients treated in this way, none developed severe side effects, though six patients experienced some adverse reaction. Twenty-five patients received anti-CTLA4 immunotherapy, while 13 received anti-PD-1 immunotherapy, with results for anti-PD-1 therapies being across-the-board more successful (full results here).

"Several years ago, a patient might have expected to live months after that diagnosis, but for many this is no longer the case," Robin says. "People are actively investigating the combination of immune checkpoint inhibits and radiation, and our data raise the possibility that PD-1 inhibitors are preferential in this setting. We hope that ongoing and future investigations will shed more light on the potential value of this combination."

Explore further: Immune and targeted therapies with radiation therapy improves outcomes for melanoma brain metastases patients

More information: Tyler P. Robin et al, Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases, Journal of Neuro-Oncology (2018). DOI: 10.1007/s11060-018-2930-5

Related Stories

Immune and targeted therapies with radiation therapy improves outcomes for melanoma brain metastases patients

September 21, 2016
Brain metastases are one of the most common complications of advanced melanoma, requiring multidisciplinary management. Patients who are diagnosed with these metastases have an expected median survival of only 4 to 5 months. ...

Is whole-brain radiation still best for brain metastases from small-cell lung cancer?

April 16, 2018
Lung cancer often metastasizes to the brain. Historically, brain metastases have been treated with whole-brain radiation therapy. However, whole-brain radiation is associated with cognitive side-effects and studies of non-small ...

Combining targeted radionuclide therapy and immunotherapy could improve melanoma survival

June 25, 2018
Research presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows that combining targeted radionuclide therapy with immunotherapy could improve the survival of patients with ...

Radiosurgery or whole-brain radiation in patients with multiple brain metastases?

December 18, 2017
Although targeted therapies have produced dramatic advances in our ability to control some types of advanced lung cancer, growth of the disease in the brain remains a major problem. Radiation is often used to treat deposits ...

Older melanoma patients have better response to immune checkpoint blockade therapy

June 13, 2018
Patient age correlates with response to immunotherapy in melanoma and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The ...

Combination of radiation and immune checkpoint therapy holds potential for lung cancer

March 16, 2017
An emerging approach for cancer treatment seeks to combine radiation therapy with immune checkpoint inhibitors (ICPIs) to more effectively control tumors in the chest with an acceptable risk of severe treatment-related side ...

Recommended for you

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.